TNF antibodies beat them all in Biologics Sales 2008
The Business Intelligence firm La Merie S.L. reported that anti-TNF antibodies were the best selling class of biologics in 2008 with total sales of US$ 16.4 bln. The most successful biologic brand in 2008 was the anti-TNF fusion protein Enbrel (etanercept) with sales of US$ 6.4 bln; the biologic with the strongest growth in 2008 was the anti-TNF antibody adalimumab from Abbott (+ US$ 1.5 bln / + 48 % vs 2007).
Erythropoietins fell down to position 4 with 2008 sales of US$ 10 bln, superseded by the class of anti-cancer antibodies (US$ 15.6 bln) and insulin products (US$ 10.9 bln) due to the continuing success of insulin analogs. The 13 major classes of biologics together posted 2008 sales of US$ 80.6 bln of which 43.4 % originated from antibody sales. The second cluster of successful classes of biologics consisted of interferon beta (US$ 5.4 bln), G-CSF (US$ 5.2 bln) and recombinant coagulation factors (US$ 4.9 bln). 2008 sales of enzyme replacement therapies recorded a strong growth from US$ 2.3 bln in 2007 to US$ 2.8 bln in 2008. These results and more were found in an elaboration prepared by La Merie Business Intelligence and published in a complimentary report. The document entitled “TOP 20 Biologics 2008” can be acquired as a free download at La Merie’s News Center.
The “TOP 20 Biologics 2008” report presents in tabular format 2008 sales figures of the TOP 20 selling single biologic products, of the 13 top-selling classes of recombinant biologicals, i.e. proteins and antibodies (excluding vaccines and peptides), and in detail the sales figures of the individual products of the 13 top selling classes of biologics plus selected other antibodies and proteins and successful peptide drugs. In addition, information is provided on brand and generic names, target, class of compound, originator and licensee companies, product category and major indications.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents
A rescuer for vital tumor-suppressor - Enzyme intervenes when cancer-fighting PTEN is bound for cell's protein-destroying machinery
Silence Therapeutics Appoints New Vice President of Research - Move Bolsters Scientific Team at Company's Research Center in Berlin
Roche acquires NimbleGen to gain entry into high-growth research microarrray market
EuropaBio Responds to the Eurobarometer on Biotechnology 2010
Evotec receives US$ 6.6 m grant for drug discovery in tuberculosis
Sartorius Reviews Fiscal 2013 Results
GVK Biosciences Joins ResearchPoint Global - Addition of India-based CRO expands reach of worldwide clinical organization
Major 'third-hand smoke' compound causes DNA damage
UCB announces start of the EXXELERATE clinical study in rheumatoid arthritis
Cangene signs agreement to supply the U.S. Department of Defense with VIG product
Mind Over Microbiome: How Mental States Impact Gut Health - New research reveals brain-gut circuit regulating immunity through microbiome modulation
